Metabolic response rates of epcoritamab plus R-CHOP in patients with previously untreated (1L) high-risk diffuse large B-cell lymphoma, including double-hit/triple-hit lymphoma: Updated EPCORE NHL-2 data.

L Falchi; Michael Roost Clausen; F Offner; S De Vos; J Brody; KM Linton; S Snauwaert; R Cordoba; J Wu; I Bykhovski; L Wang; A Rana; D Belada

doi:10.1200/JCO.2023.41.16_suppl.7519

Metabolic response rates of epcoritamab plus R-CHOP in patients with previously untreated (1L) high-risk diffuse large B-cell lymphoma, including double-hit/triple-hit lymphoma: Updated EPCORE NHL-2 data.

L Falchi, Michael Roost Clausen, F Offner, S De Vos, J Brody, KM Linton, S Snauwaert, R Cordoba, J Wu, I Bykhovski, L Wang, A Rana, D Belada

Division of Cancer Sciences (L5)

Research output: Contribution to journal › Meeting Abstract › peer-review

Original language	English
Number of pages	1
Journal	Journal of Clinical Oncology
Volume	41
Issue number	16
DOIs	https://doi.org/10.1200/JCO.2023.41.16_suppl.7519
Publication status	Published - 1 Jun 2023

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1200/JCO.2023.41.16_suppl.7519

Cite this

Falchi, L., Clausen, M. R., Offner, F., De Vos, S., Brody, J., Linton, KM., Snauwaert, S., Cordoba, R., Wu, J., Bykhovski, I., Wang, L., Rana, A., & Belada, D. (2023). Metabolic response rates of epcoritamab plus R-CHOP in patients with previously untreated (1L) high-risk diffuse large B-cell lymphoma, including double-hit/triple-hit lymphoma: Updated EPCORE NHL-2 data. Journal of Clinical Oncology, 41(16). https://doi.org/10.1200/JCO.2023.41.16_suppl.7519

@article{bc78a61c5e76454b83a77295b38d7b8b,

title = "Metabolic response rates of epcoritamab plus R-CHOP in patients with previously untreated (1L) high-risk diffuse large B-cell lymphoma, including double-hit/triple-hit lymphoma: Updated EPCORE NHL-2 data.",

author = "L Falchi and Clausen, {Michael Roost} and F Offner and {De Vos}, S and J Brody and KM Linton and S Snauwaert and R Cordoba and J Wu and I Bykhovski and L Wang and A Rana and D Belada",

year = "2023",

month = jun,

day = "1",

doi = "10.1200/JCO.2023.41.16_suppl.7519",

language = "English",

volume = "41",

journal = "Journal of Clinical Oncology",

issn = "0732-183X",

publisher = "American Society of Clinical Oncology",

number = "16",

}

Falchi, L, Clausen, MR, Offner, F, De Vos, S, Brody, J, Linton, KM, Snauwaert, S, Cordoba, R, Wu, J, Bykhovski, I, Wang, L, Rana, A & Belada, D 2023, 'Metabolic response rates of epcoritamab plus R-CHOP in patients with previously untreated (1L) high-risk diffuse large B-cell lymphoma, including double-hit/triple-hit lymphoma: Updated EPCORE NHL-2 data.', Journal of Clinical Oncology, vol. 41, no. 16. https://doi.org/10.1200/JCO.2023.41.16_suppl.7519

Metabolic response rates of epcoritamab plus R-CHOP in patients with previously untreated (1L) high-risk diffuse large B-cell lymphoma, including double-hit/triple-hit lymphoma: Updated EPCORE NHL-2 data. / Falchi, L; Clausen, Michael Roost; Offner, F et al.
In: Journal of Clinical Oncology, Vol. 41, No. 16, 01.06.2023.

Research output: Contribution to journal › Meeting Abstract › peer-review

TY - JOUR

T1 - Metabolic response rates of epcoritamab plus R-CHOP in patients with previously untreated (1L) high-risk diffuse large B-cell lymphoma, including double-hit/triple-hit lymphoma

T2 - Updated EPCORE NHL-2 data.

AU - Falchi, L

AU - Clausen, Michael Roost

AU - Offner, F

AU - De Vos, S

AU - Brody, J

AU - Linton, KM

AU - Snauwaert, S

AU - Cordoba, R

AU - Wu, J

AU - Bykhovski, I

AU - Wang, L

AU - Rana, A

AU - Belada, D

PY - 2023/6/1

Y1 - 2023/6/1

UR - https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=pure_starter&SrcAuth=WosAPI&KeyUT=WOS:001053772003462&DestLinkType=FullRecord&DestApp=WOS

U2 - 10.1200/JCO.2023.41.16_suppl.7519

DO - 10.1200/JCO.2023.41.16_suppl.7519

M3 - Meeting Abstract

SN - 0732-183X

VL - 41

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

IS - 16

ER -

Metabolic response rates of epcoritamab plus R-CHOP in patients with previously untreated (1L) high-risk diffuse large B-cell lymphoma, including double-hit/triple-hit lymphoma: Updated EPCORE NHL-2 data.

UN SDGs

Access to Document

Other files and links

Cite this